Halozyme
HALO
Performance
About Halozyme
Halozyme is a biotechnology company focused on disruptive drug delivery technologies and a robust commercial portfolio. It pioneers subcutaneous drug delivery with its ENHANZE platform, enabling partners to administer biologics more conveniently, potentially improving patient experience and treatment adherence. The company emphasizes reinvention of the patient experience through its delivery technologies and a broad product portfolio, supporting healthcare providers and patients globally.
Recent News
Alteogen Wins PTAB Ruling, Halting Halozyme's Challenge to ALT‑B4 Manufacturing Patent
GSK Joins Growing PD-1 SubQ Push With Alteogen Alliance Worth up to $285M+
Halozyme and Oruka Sign Agreement for Hypercon Technology
Halozyme Q1 Revenue Jumps 42% to $377 M on ENHANZE Therapy Surge
Halozyme Launches $1 Billion Share Buyback as Q1 Earnings Beat Expectations
Evotec Slashes Staff as Turnaround Plan Gathers Pace
Halozyme Diversifies in Drug Delivery with Surf Bio Buy
Halozyme Buys Drug Delivery Biotech Surf Bio; Sanofi Backs Sensorion